Cephalexin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Cephalexin: From Systemic Antibacterial Use to Chronic Otitis Media
One-Sentence Summary
Cephalexin is a first-generation oral cephalosporin antibiotic. The TxGNN model predicts it may be effective for chronic otitis media. The supporting evidence is thin: 0 registered clinical trials and 20 publications, most of them microbiology surveys or studies of other antibiotics.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the supplied SAHPRA registration data (cephalexin is a systemic antibacterial) |
| Predicted New Indication | Chronic otitis media |
| TxGNN Prediction Score | 98.55% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the supplied data. Cephalexin is a beta-lactam that inhibits bacterial cell wall synthesis. It is active against Gram-positive organisms such as Staphylococcus aureus and streptococci, which are found in chronic ear infections.
Chronic otitis media is often a bacterial infection, so an antibacterial is a plausible fit. The fit is only partial, though. Cephalexin has limited activity against H. influenzae, anaerobes and Pseudomonas, and these organisms are prominent in chronic suppurative disease. Much of the retrieved literature concerns other cephalosporins (cefaclor, cefdinir, cefroxadine), so it supports the drug class more than cephalexin itself.
Cephalexin may already be labelled for otitis media in some jurisdictions. If so, this finding reflects existing use rather than true repurposing. This was not verified from the supplied data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Only papers that mention cephalexin or address chronic otitis media directly are listed. None is a modern trial of oral cephalexin in chronic otitis media.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6361325 | 1983 | RCT (double-blind) | Jpn J Antibiot | Cefroxadine vs cephalexin (250 mg four times daily) in acute suppurative otitis media and acute exacerbation of chronic suppurative otitis media. Outcomes were almost equal in the acute form. |
| 8177625 | 1994 | Retrospective clinical study | Pediatr Infect Dis J | 69 children with chronic suppurative otitis media. Mixed aerobic and anaerobic flora was common, and 58% of patients had beta-lactamase-producing bacteria. Therapy effective against anaerobes was favoured. The role of cephalexin is unclear. |
| 6798820 | 1981 | Observational | Acta Otolaryngol | Oral cephalexin vs cephalexin ear drops in chronic otitis media. Bacterial counts in otorrhoea fell more with ear drops than with oral dosing. Only a capsule is registered in South Africa. |
| 22737435 | 2011 | Observational (microbiology) | Iran Red Crescent Med J | Bacterial isolates and antimicrobial susceptibility in chronic suppurative otitis media patients in Kerman, Iran. |
| 11838568 | 2001 | Review | Indian J Pediatr | Overview of upper respiratory tract infections including otitis media. Most are viral and do not need antibiotics. |
| 2685215 | 1989 | Cohort | Nihon Jibiinkoka Gakkai Kaiho | Clinical and bacteriological factors in delayed recovery of otitis media with effusion in children. |
| 7200999 | 1982 | Pharmacokinetic study | J Infect Dis | Middle ear fluid penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole and trimethoprim-sulfamethoxazole. Cephalexin was not studied. |
| 1920724 | 1991 | Observational (bacteriology) | JAMA | Bacteriology of acute otitis media in adults. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 37/20.1.1/0618 | Belex | Capsule (oral) | Not stated in the supplied data |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction has no registered trials behind it, and the literature is mostly indirect (microbiology surveys and studies of other cephalosporins).
- Cephalexin’s spectrum has gaps against organisms prominent in chronic suppurative disease.
- The one study that used cephalexin directly in chronic otitis media (1981) favoured a topical route, and no topical product is registered in South Africa.
- Acute suppurative otitis media (rank 2 in this pack) has more direct but dated comparative evidence and may be the better research question.
To proceed, the following is needed:
- The SAHPRA Professional Information (PI) for warnings, contraindications and approved indications. Safety review cannot start without it.
- Confirmation of whether otitis media is already a labelled indication for cephalexin, which would make this label use rather than repurposing.
- Mechanism of action data from DrugBank.
- Current South African susceptibility data for the main pathogens in chronic otitis media.
- Modern comparative trial evidence for cephalexin in chronic otitis media.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.